CAMP4 Therapeutics Corp [CAMP] stock is trading at $2.32, up 20.83%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CAMP shares have gain 32.57% over the last week, with a monthly amount drifted -23.43%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Piper Sandler started tracking the stock with Overweight rating on November 05, 2024, and set its price target to $18. On November 05, 2024, JP Morgan initiated with a Overweight rating and assigned a price target of $23 on the stock.
CAMP4 Therapeutics Corp [CAMP] stock has fluctuated between $1.61 and $12.30 over the past year. Currently, Wall Street analysts expect the stock to reach $12.5 within the next 12 months. CAMP4 Therapeutics Corp [NASDAQ: CAMP] shares were valued at $2.32 at the most recent close of the market. An investor can expect a potential return of 438.79% based on the average CAMP price forecast.
Analyzing the CAMP fundamentals
Gross Profit Margin for this corporation currently stands at 0.36% with Operating Profit Margin at -0.05%, Pretax Profit Margin comes in at -0.5%, and Net Profit Margin reading is -0.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -2.08 and Total Capital is -0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 16.81.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.9600 points at the first support level, and at 1.5900 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.5400, and for the 2nd resistance point, it is at 2.7500.
Ratios To Look Out For
For context, CAMP4 Therapeutics Corp’s Current Ratio is 6.92. Also, the Quick Ratio is 6.92, while the Cash Ratio stands at 0.39.
Transactions by insiders
Recent insider trading involved Northpond Ventures II GP, LLC, 10% Owner, that happened on Oct 15 ’24 when 0.76 million shares were purchased. 10% Owner, AH Equity Partners Bio I, L.L. completed a deal on Oct 15 ’24 to buy 0.73 million shares. Meanwhile, 10% Owner Enavate Sciences GP, LLC bought 1.36 million shares on Oct 15 ’24.
